Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

Similar articles for PubMed (Select 21905086)

1.

Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder.

Frenkl T, Railkar R, Shore N, Bailen J, Sutherland S, Burke J, Scott BB, Ruddy M, Beals C.

Neurourol Urodyn. 2012 Jan;31(1):69-74. doi: 10.1002/nau.21094. Epub 2011 Sep 8.

PMID:
21905086
2.

Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.

Malone-Lee JG, Al-Buheissi S.

BJU Int. 2009 Apr;103(7):931-7. doi: 10.1111/j.1464-410X.2009.08361.x. Epub 2009 Mar 5.

PMID:
19281469
3.
4.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

PMID:
20132103
5.

Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Chapple CR, Van Kerrebroeck PE, J√ľnemann KP, Wang JT, Brodsky M.

BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.

PMID:
18647298
6.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
7.

Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.

Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ.

Neurourol Urodyn. 2009;28(1):47-51. doi: 10.1002/nau.20583.

PMID:
19089890
8.
9.

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.

Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026. Epub 2008 Nov 24.

PMID:
19070418
10.

Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.

Nitti VW, Rovner ES, Bavendam T.

BJU Int. 2010 May;105(9):1268-75. doi: 10.1111/j.1464-410X.2009.09037.x. Epub 2009 Nov 4.

PMID:
19889062
11.

Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.

Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH.

J Obstet Gynaecol Res. 2011 Aug;37(8):1084-91. doi: 10.1111/j.1447-0756.2010.01493.x. Epub 2011 Apr 19.

PMID:
21501328
12.

Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder.

Marencak J, Cossons NH, Darekar A, Mills IW.

Neurourol Urodyn. 2011 Jan;30(1):75-82. doi: 10.1002/nau.20928. Epub 2010 Sep 30.

PMID:
20886571
13.
14.

Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity.

Salvatore S, Serati M, Digesu GA, Triacca P, Uccella S, Khullar V, Bolis P.

Int Urogynecol J Pelvic Floor Dysfunct. 2008 May;19(5):701-4. Epub 2007 Dec 8.

PMID:
18066482
15.

Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: a real-time NIRS-urodynamics study.

Sakakibara, Tateno F, Yano M, Takahashi O, Sugiyama M, Ogata T, Kishi M, Tsuyusaki Y, Yamamoto T, Uchiyama T, Yamanishi T, Shibata C.

Neurourol Urodyn. 2014 Sep;33(7):1110-5. doi: 10.1002/nau.22471. Epub 2013 Aug 29.

PMID:
24038213
16.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
17.

The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.

Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z.

BJU Int. 2007 Jul;100(1):107-10.

PMID:
17552957
18.

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group.

Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.

PMID:
18639327
19.

Antimuscarinic effects on current perception threshold: a prospective placebo control study.

Vijaya G, Digesu GA, Derpapas A, Hendricken C, Fernando R, Khullar V.

Neurourol Urodyn. 2012 Jan;31(1):75-9. doi: 10.1002/nau.21194. Epub 2011 Oct 28.

PMID:
22038939
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk